Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130

Benzinga Newsdesk www.benzinga.com Positive 74.9%

Neg 0% Neu 0% Pos 74.9%

Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.